The Global mRNA synthesis and manufacturing services market size valued at US$ 53278.8 Million in 2021 and it is expected decline to reach US$ 22,634.5 Million in 2031, recording a CAGR of -3.4% during the period of 2022-2031.In 2021 market has grown exponentially due to the success of the COVID-19 vaccines, and it has created a massive demand for a consistent supply of vaccines. However, in 2022 market is expected to decrease at the growth rate of -42.0%. The mRNA Synthesis and Manufacturing Services market other than COVID 19 application are under development which offers immense growth and penetration opportunities in the forecast period. By region, Asia Pacific dominates the mRNA synthesis and manufacturing services market with share of 33.4% of total global market.
Due to its versatile and flexible nature, mRNA is an excellent platform for developing prophylactic or therapeutic vaccines against various chronic and infectious diseases. Compared to conventional medicines, mRNA vaccines have higher effectiveness, improved immunogenicity, and required less manufacturing cost. The constant innovations and improvements in mRNA synthesis and manufacturing services are expected to propel the market growth of mRNA synthesis and manufacturing services over the forecast period. During the current Covid-2019 pandemic, many companies have chosen mRNA vaccine technology to combat coronavirus. For instance, in November 2020, Pfizer Inc. and BioNTech SE announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 had demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection.
The increasing need for gene therapies, growing chronic and infectious diseases, and the rising number of clinical trials for cancer therapies and infectious diseases are likely to evolve the mRNA synthesis and manufacturing services market at a considerable rate in the next few years. Furthermore, advanced medical technologies, increasing customizable facilities, improving quality and efficacy services, and novel innovations by pharmaceutical companies enhance the market growth. However, the lack of flexible, sustainable, and cost-effective manufacturing processes hinders the growth of mRNA synthesis and manufacturing services.Segmentation of mRNA synthesis and manufacturing services market includes Products, Applications, Scale of Operation, and Region. The market can be segmented into API and Drug Products based on Products. By Applications, the market is categorized into Infectious Disease Vaccines, Other Vaccines, Therapeutics and Others. Based on the Scale of Operation, the market is segmented into Research / Preclinical, Clinical, and Commercial. Regionally, the mRNA synthesis and manufacturing services market can be divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America, followed by Europe and the Asia Pacific, holds the maximum share of this market due to increased research and development expenditure, increased prevalence of infectious diseases, and the fast adoption of advanced technologies.
Some of the key players of the mRNA synthesis and manufacturing services market are Eurogentec, Aldevron, eTheRNA (Etherna Immunotherapies), biosynthesis, TriLink BioTechnologies, Biomay, Jena Biosciences, APExBIO, CELLSCRIPT, Thermo Fisher Scientific, New England Biolabs, CureVac, Moderna, BioNTech (Pfizer), Translate Bio, Ethris (AstraZeneca), Kernal Biologics, Silence Therapeutics, Tiba Biotechnology, In-Cell-Art, Anima Biotch, H3 Biomedicine Inc., Arcturus Therapeutics, eFFECTOR Therapeutics, Inc., Ionis Pharmaceuticals, Inc., Stemirna Therapeutics Co., Ltd., Skyhawk Therapeutics, Inc, RNAimmune (Sirnaomics), Ziphius Therapeutics NV, miRagen Therapeutics, Inc., Strand Therapeutics Inc., and other Prominent Players.
